B. Schrage
Karolinska Institutet
17 Papers
50 Citations
B. Schrage is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Heart failure & Population. The author has an hindex of 5, co-authored 17 publications. Previous affiliations of B. Schrage include University of Kiel & University of Hamburg.
Chat about Author
Papers
Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
B. Schrage,B. Schrage,Alicia Uijl,Alicia Uijl,Lina Benson,Dirk Westermann,Marcus Ståhlberg,Davide Stolfo,Ulf Dahlström,Cecilia Linde,Frieder Braunschweig,Gianluigi Savarese +11 more
TL;DR: In a contemporary HFrEF population, ICD for primary prevention was underused although it was associated with reduced short- and long-term all-cause mortality, consistent across all the investigated subgroups.
85
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.
Peter Moritz Becher,Peter Moritz Becher,B. Schrage,B. Schrage,Lina Benson,Marat Fudim,Marat Fudim,Carin Corovic Cabrera,Ulf Dahlström,Giuseppe M.C. Rosano,Ewa A. Jankowska,Stefan D. Anker,Lars H. Lund,Lars H. Lund,Gianluigi Savarese,Gianluigi Savarese +15 more
TL;DR: In this article, the authors used multivariable logistic regressions to assess patient characteristics independently associated with ID testing and use of ferric carboxymaltose (FCM) and its predictors in patients with ID.
54
Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design
Gianluigi Savarese,Camilla Settergren,B. Schrage,Tonje Thorvaldsen,Ida Löfman,Ulrik Sartipy,Ulrik Sartipy,Linda Mellbin,Andrea Meyers,Soulmaz Fazeli Farsani,Martina Brueckmann,Martina Brueckmann,Kimberly G. Brodovicz,Ola Vedin,Ola Vedin,Folkert W. Asselbergs,Folkert W. Asselbergs,Ulf Dahlström,Francesco Cosentino,Lars H. Lund +19 more
TL;DR: HFpEF is distinguished from HFmrEF and HFrEF by more comorbidities, non-CV events, but lower effect of T2DM and CKD on events.
43
Use of Sodium‐Glucose Co‐transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry
Peter Moritz Becher,Peter Moritz Becher,B. Schrage,B. Schrage,Giulia Ferrannini,Lina Benson,Javed Butler,Juan Jesus Carrero,Francesco Cosentino,Francesco Cosentino,Ulf Dahlström,Linda Mellbin,Linda Mellbin,Giuseppe Rosano,Gianfranco Sinagra,Davide Stolfo,Davide Stolfo,Lars H. Lund,Lars H. Lund,Gianluigi Savarese,Gianluigi Savarese +20 more
TL;DR: In this paper, the authors investigated the association between SGLT2i use and outcomes in real-world heart failure patients with Type 2 diabetes mellitus and found that SGL2i was associated with a 30% lower risk of cardiovascular (CV) death/first HF hospitalisation (hazard ratio 0.70, 95% confidence interval 0.52-0.95).
39
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials.
B. Schrage,B. Schrage,Benedikt N Beer,Gianluigi Savarese,Salim Dabboura,Isabell Yan,Jonas Sundermeyer,Peter Moritz Becher,Hanno Grahn,Moritz Seiffert,Alexander M. Bernhardt,Holger Thiele,Jacob E. Møller,Stefan Kluge,Hermann Reichenspurner,Paulus Kirchhof,Stefan Blankenberg,Dirk Westermann +17 more
TL;DR: In this paper, the authors investigated the eligibility of MCS patients in randomised controlled trials (RCTs) and found that only 31.8% of the patients were eligible for any study and the lowest eligibility was observed for DanGer-SHOCK (11.9%) and the highest for IABP-ShOCK II (26.9%).
38